Insider Selling: Health Catalyst (NASDAQ:HCAT) Director Sells 47,997 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Julie Larson-Green sold 47,997 shares of Health Catalyst stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $2.67, for a total value of $128,151.99. Following the transaction, the director owned 73,573 shares of the company’s stock, valued at $196,439.91. The trade was a 39.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Health Catalyst Stock Performance

NASDAQ:HCAT traded down $0.03 on Tuesday, hitting $2.61. The company’s stock had a trading volume of 493,261 shares, compared to its average volume of 704,965. Health Catalyst, Inc. has a one year low of $2.02 and a one year high of $8.52. The firm has a market capitalization of $184.61 million, a P/E ratio of -1.64 and a beta of 1.72. The stock has a fifty day moving average of $2.83 and a two-hundred day moving average of $3.30. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.46.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Monday, November 10th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.01. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%.The business had revenue of $76.32 million for the quarter, compared to analyst estimates of $75.05 million. Research analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Institutional Trading of Health Catalyst

Hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Health Catalyst by 7.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock valued at $163,000 after buying an additional 2,624 shares during the period. Campbell & CO Investment Adviser LLC grew its stake in shares of Health Catalyst by 9.7% in the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 43,051 shares of the company’s stock valued at $162,000 after buying an additional 3,808 shares during the period. The Manufacturers Life Insurance Company increased its stake in Health Catalyst by 19.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company’s stock valued at $100,000 after purchasing an additional 4,341 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Health Catalyst by 71.7% during the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock worth $47,000 after acquiring an additional 6,832 shares in the last quarter. Finally, Probity Advisors Inc. grew its holdings in Health Catalyst by 20.5% during the third quarter. Probity Advisors Inc. now owns 45,161 shares of the company’s stock worth $129,000 after buying an additional 7,671 shares in the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HCAT. BTIG Research restated a “neutral” rating on shares of Health Catalyst in a research note on Friday, September 5th. Stifel Nicolaus lowered their price target on shares of Health Catalyst from $4.50 to $3.75 and set a “hold” rating on the stock in a report on Tuesday, November 11th. Piper Sandler downgraded shares of Health Catalyst from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $8.00 to $4.00 in a research report on Wednesday, August 27th. Canaccord Genuity Group decreased their target price on Health Catalyst from $9.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, August 29th. Finally, KeyCorp lowered their target price on Health Catalyst from $5.00 to $4.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Health Catalyst has a consensus rating of “Hold” and an average price target of $4.36.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.